This is a randomized, multi-center, double-blind, placebo-controlled, multi-dose, parallel-group study. Approximately 300 subjects (150 per group) 16 years of age and older with a current (within 24 hours from Visit 1) Grade I or II ankle sprain, and who meet all eligibility criteria, will be randomized into the study and will receive either the active treatment (SST-0225 ibuprofen cream), or matching placebo. Subjects will apply an amount equivalent to a 4 inch line of investigational product to the affected ankle approximately every 4-6 hours. At Visit 1 two doses will be applied at the site. All subsequent doses of the investigational product will be applied every 4 to 6 hours with a total of 4 doses in a 24 hour period. Duration of treatment with the investigational product is 7 days.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
305
Placebo cream
SST-0225 Topical Ibuprofen Cream
Ce3
Guilford, Connecticut, United States
24 Hour SPID
Tme weighted summed pain intensity on movement difference from baseline over the first 24 hours (SPID24) following the first application of study medication on Day 1
Time frame: 24 Hours
Time to onset of confirmed perceptible pain relief and onset of meaningful pain relief
• Time to onset of confirmed perceptible pain relief and onset of meaningful pain relief over the four-hour in-office phase of the study.
Time frame: First 4 hours
Mean change from baseline in subject reported pain intensity
• Mean change from baseline in subject reported pain intensity (at rest and on movement) and pain relief (on movement only) as assessed at 15 minutes, 30 minutes, and hourly up to 4 hours following the first application on Day 1.
Time frame: First 4 hours
Mean change from baseline in pain scores on movement
• Mean change from baseline in pain scores on movement at hours 6, 8, 10, 12, 20 and 24 hours over the first 24 hours.
Time frame: First 24 hours
Percent of subjects with > 15%, > 30% and > 50% reductions in pain intensity
• Percent of subjects with \> 15%, \> 30% and \> 50% reductions in pain intensity from baseline at 24 hours.
Time frame: First 24 hours
Subject's global evaluation of investigational product
• Subject's global evaluation of investigational product evaluated at Days 2, 4 and 7 (or End-of-Study) based on a 5 point scale.
Time frame: 7 days
Use of rescue medication including time to first use
• Use of rescue medication including time to first use (first 12 hours), proportion of subjects using rescue and amount of rescue medication used.
Time frame: 7 days
Change from baseline in pain scores on movement
• Change from baseline in pain scores on movement at time of each dose on Days 2-7.
Time frame: 7 days
Number and percent of patients with systemic and local (skin) self-reported adverse events
Number and percent of patients with systemic and local (skin) self-reported adverse events.
Time frame: 7 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.